ADPT
HealthcareAdaptive Biotechnologies Corporation
$16.17
+$0.26 (+1.63%)
Jan 5, 2026
Price History (1Y)
Analysis
Adaptive Biotechnologies Corporation is a healthcare company in the biotechnology industry with a market capitalization of $2.47B and 619 employees. It operates within the sector of Healthcare. The company's financial health indicates mixed results. The profitability margins are as follows: gross margin at 65.1%, operating margin at 10.9%, and profit margin at -31.5%. Returns on equity and assets are also negative, at -37.2% and -9.3%, respectively. The balance sheet shows a debt-to-equity ratio of 104.60 and cash reserves of $212.77M against outstanding debt of $213.64M. Adaptive Biotechnologies' valuation context is characterized by a forward P/E ratio of -28.16, an EV/EBITDA ratio of -40.42, and a price-to-book ratio of 12.07. Revenue growth has been significant at 102.4% year-over-year, while earnings growth is not provided due to the "N/A" designation in available facts.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. It has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Visit website →Key Statistics
- Market Cap
- $2.47B
- P/E Ratio
- N/A
- 52-Week High
- $20.76
- 52-Week Low
- $5.97
- Avg Volume
- 2.24M
- Beta
- 2.18
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 619